ADDvise Groups revenue and EBT for Q4 2018 better than anticipated – Regulatory information

25-01-2019   Regulatory press release

ADDvise Group has made a preliminary assessment of the Group revenue and earnings before tax (EBT) for the fourth quarter 2018. Revenue and EBT show strong improvement when compared to the fourth quarter 2017.

Revenue in Q4 2018 is estimated to reach 73 MSEK compared to 62 MSEK in Q4 2017, an increase by over 17 %. Earnings before tax (EBT) in Q4 2018 is estimated to reach 1,4 MSEK compared to -7,4 MSEK in Q4 2017.

-        The EBT is driven by the positive revenue trend combined with the effect from synergies in acquired businesses, says Rikard Akhtarzand in a comment to the preliminary result for Q4.

Revenue for the full year 2018 is estimated to reach 268 MSEK compared to 240 MSEK for the full year 2017, an increase by more than 11 %. Earnings before tax (EBT) is estimated to reach -2,7 MSEK for 2018. EBT for the full year in 2017 reached -10,6 MSEK.

The numbers are preliminary, and the fourth quarter report will be released February 21st 2019.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 25th 2019 at 13:15 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…